Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
XRAY · against 588 other Healthcare companies listed in US-listed
Ranked #98 of 589 · scores higher than 82% of peers
Bars: peers in each 10-point band of the valuation score45 peers with a valuation score of 60–69, including XRAY · Click a bar to see the companies
Mainly thanks to its free cash flow yield and EBITDA yield, which are stronger than most Healthcare peers.
| Metric | XRAY | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 577 reported | -28.1% | -4.3% | 16% | 30% | |
| EBITDA yieldHigher is better · 578 reported | 13.1% | -0.8% | 92% | 50% | |
| Free cash flow yieldHigher is better · 553 reported | 7.4% | -2.3% | 90% | 20% | |
| Book yieldHigher is better · 587 reported | 67.6% | 25.9% | 83% | Context only |
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 256M USD | 98 | 80 | |
| 2 | 595M USD | 96 | 97 | |
| 2 | 433M USD | 96 | 81 | |
| 2 | 289M USD | 96 | 57 | |
| 2 | 810M USD | 96 | 69 | |
| 98 | 4.4B USD | 66 | 66 | |
| 98 | 3.2B USD | 66 | 65 | |
| 98 | 4.0B USD | 66 | 56 | |
| 98 | 171.0B USD | 66 | 45 | |
| 98 | 1.9B USD | 66 | 38 | |
| 106 | 6.6B USD | 65 | 61 | |
| 106 | 22.6B USD | 65 | 59 | |
| 106 | 363.0B USD | 65 | 47 | |
| 109 | 243M USD | 64 | 56 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score